Markets

Direct Investment

Highlights

Trends/Policies

Biotech drug to play major role

By Su Yue (chinadaily.com.cn)
Updated: 2006-09-22 08:52

Pharmaceutical technology has been playing an increasingly important role for large-scale medicine producers, and analysis indicates that 60 percent of their sales revenue will come from biotech medicines by 2010.

It is predicted that the annual sales volume of monoclonal antibodies (mAbs) will reach US$18 billion, tantamount to a 26.2 percent compound annual growth rate (CAGR). The CAGR figure for small molecule medicines for this period is expected to remain at the low level of 0.9 percent.

Many pharmaceutical firms have devoted  efforts in developing small molecule  medicines for the past few years, in the hopes of effectively improving their sales revenue. However, this concept needs to be changed since the biotech market, especially that of monoclonal medicines, is growing dramatically.

......

The full text is available in the Sept-Oct Issue ofChina Medicine.